InsidersTradesSigma
Total declarations
Company
▲ Purchases (11 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Fraser Craig, Chairman & CEO. Officer active across 1 companies, notably Windtree Therapeutics INC. Cumulatively, 12 reports have been logged. Total volume traded: €32k. The latest transaction was disclosed on 29 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
€2,7837,000 shares@ €0.39760.49% mcap8.7% of flow
Common Stock
SEC:0001437749-22-016227:0·
Ideal exit: 26 Mar 2023 (T+270)
€1,7872,000 shares@ €0.89330.31% mcap5.6% of flow
Common Stock
SEC:0001437749-22-006612:0·
Ideal exit: 11 Dec 2022 (T+270)
€2,6873,000 shares@ €0.89560.47% mcap8.3% of flow
Common Stock
SEC:0001437749-22-006313:0·
Ideal exit: 10 Dec 2022 (T+270)
0166,900 shares0
Common Stock
SEC:0001437749-22-005417:0·
€1,309930 shares@ €1.407410.5% of flow
Common Stock
SEC:0001437749-21-027198·
Ideal exit: 16 Aug 2022 (T+270)
€1,309930 shares@ €1.40740.23% mcap4.1% of flow
Common Stock
SEC:0001437749-21-027198:0·
Ideal exit: 16 Aug 2022 (T+270)
€1,323930 shares@ €1.422110.6% of flow
Common Stock
SEC:0001437749-21-027085·
Ideal exit: 15 Aug 2022 (T+270)
€1,323930 shares@ €1.42210.23% mcap4.1% of flow
Common Stock
SEC:0001437749-21-027085:0·
Ideal exit: 15 Aug 2022 (T+270)
€4,9033,000 shares@ €1.634439.3% of flow
Common Stock
SEC:0001437749-21-024196·
Ideal exit: 19 Jul 2022 (T+270)
€4,9033,000 shares@ €1.63440.86% mcap15.2% of flow
Common Stock
SEC:0001437749-21-024196:0·
Ideal exit: 19 Jul 2022 (T+270)
€4,9263,000 shares@ €1.64239.5% of flow
Common Stock
SEC:0001437749-21-023910·
Ideal exit: 16 Jul 2022 (T+270)
€4,9263,000 shares@ €1.6420.86% mcap15.3% of flow
Common Stock
SEC:0001437749-21-023910:0·
Ideal exit: 16 Jul 2022 (T+270)
12 of 12 declarations
About Fraser Craig
Craig Fraser is the President and CEO of WINDTREE THERAPEUTICS INC. He leads the company's operations and oversees the implementation of its development strategy, contributing to innovation in the biotechnology sector.
